BioWorld-International-2004-12-22
Pharmos Crashes On Data From Phase III Brain Study
Pharmos Crashes On Data From Phase III Brain Study
Once high on Pharmos Corp.'s cannabinoid-receptor drug for brain injury, investors came down hard following news that the compound failed in a pivotal Phase III trial.(BioWorld International)

